Drug-Eluting Stents: Market Research Report

Date: May 1, 2012
Pages: 282
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DE39A061330EN
Leaflet:

Download PDF Leaflet

Drug-Eluting Stents: Market Research Report
This report analyzes the worldwide markets for Drug-Eluting Stents in US$ Million.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of the World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 39 companies including many key and niche players such as Abbott Vascular, Boston Scientific, Inc., Biosensors International Pte Ltd., Medtronic, Inc., and MIV Therapeutics Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.MARKET OVERVIEW

Recession Plummets Global DES Market
Major Issues and Trends
Recession Hits Cardiovascular Device Makers
Changing Fortunes in the Global DES Industry
Global Market Recovers From Safety Issue Shambles
Competition Intensifies as New Products Make Way in to the Market
Drug-Eluting Stents Transforming the Face of Interventional Cardiology Market

Table 1. Global Stents Market by Type (2011): Percentage Breakdown of Value Sales for Drug-Eluting Stents and Bare-Metal Stents (includes corresponding Graph/Chart)

Concerns over Adverse Effects Remain A Major Snag
Potential Decline in Hospital Revenues
Shift in Pricing Models to Increase Innovation Levels
Glaring Lack of Health-Related Initiatives the World Over
Bioabsorbable Stents – Abbott Makes a Headstart with Absorb

2.COMPETITIVE LANDSCAPE

A Brief Introduction to DES
Suitable Patient Types for Drug-Eluting Stents
J&J Exit from DES Market Improves Prospects for Competitors
Drug-Eluting Stents - Competitive Landscape
World Drug-Eluting Stents Market (2002-2012): DES Brands Launched by Major Manufacturers– Abbott Vascular Inc., Boston Scientific Corp., Cordis (Johnson & Johnson), Medtronic Inc., and Intersect Ent
Boston Scientific Leads Global DES Market, Abbott Closes In

Table 2. World Drug Eluting Stents Market (2010): Market Share Breakdown of Value Sales by Leading Players - Boston Scientific, Abbott, Medtronic, and Others (includes corresponding Graph/Chart)

Xience and Promus Take the Lead

Table 3. World Drug Eluting Stents Market (2010): Market Share Breakdown of Value Sales by Leading Brands - Xience V, Promus/Element, Taxus, Endeavor and Others (includes corresponding Graph/Chart)

Major DES Drugs Available in the Market
Sirolimus
Paclitaxel
Everolimus
Zotarolimus
Biolimus
Other Treatments Available for Treating In-Stent Restenosis
Select Leading Drug-Eluting Stent Products in the Market
XIENCE V (Abbott)
PROMUS® (Boston Scientific)
XIENCE PRIME (Abbott)
TAXUS® Liberte® Atom™ (Boston Scientific)
ENDEAVOR (Medtronics)
TAXUS (Boston Scientific)

3.CORONARY STENTING – AN INSIGHT

Cardiovascular Diseases – A Brief Description

Table 4. World Market for Cardiovascular Therapies (2011): Percentage Share Breakdown of Value Sales by Product Category-Drug-Eluting Stents, Cardiac Resynchronization Therapy, Cardiac Markers, Portable Automated External Defibrillators, and Angiogenesis/Gene Therapy (includes corresponding Graph/Chart)

Coronary Heart Disease
Traditional Methods of Treating Blockage of Coronary Arteries
Percutaneous Transluminal Coronary Angioplasty (PTCA)
Coronary Artery Bypass Graft (CABG)
Restenosis
Evolution of Coronary Stents as a Replacement for Traditional Methods
What are Coronary Stents?
How is Coronary Stenting Performed – Procedure
Risks and Problems Associated with Placing a Stent
Restenosis Still Pervasive Even after the Use of Stents
Market Analysis for Coronary Stents
By Region/Country

Table 5. World Market for Coronary Stents (2011): Percentage Share Breakdown of Value Sales by Region/Country -US, Japan, Europe, Japan, and Rest of World (includes corresponding Graph/Chart)

In-Stent Restenosis – Outcome of Bare Metal Stents
In-Stent Restenosis – Definition
Causes of In-Stent Restenosis

4.COST AND PRICE ECONOMICS

Cost Evaluation of DES
Initial Procedural Costs Remain High

Table 6. Average Price Per DES Unit for the Period 2004-2005
Table 7. Worldwide Average Stent Prices (2002-2005): Breakdown of Regions by Drug Eluting Stents and Bare Metal Stents

Follow-Up Costs Provide Relief

Table 8. A Comparative Presentation of Long-Term Costs of DES and CABG

Conversion of CABG Procedures to DES
Impact of DES on Indirect Costs

5.RESEARCH AND DEVELOPMENT INITIATIVES - A HISTORIC PERSPECTIVE BUILDER

Boston Completes European and Intercontinental Enrollment Phases
Medtronic To Start Clinical Study
Guidant Accomplishes Patient Enrollment
Abbott Receives FDA Approval for Initiation of ZoMaxx Clinical Trials
Medtronic Commences Endeavor III Clinical Trial
MIV Therapeutics Completes Drug-Eluting Stent Coating R&D Program
Guidant Conducts First Implant as Part of Drug Eluting Stent Trial
Medtronic’s Endeavor Drug Eluting Stent Shows Positive Results
Cypher™ Coronary Stent Trials Show Restenosis Rates Decline by 5.1%
Boston Scientific Demonstrates Positive Results for Taxus IV Clinical Trial
Medtronic Initiates Endeavor II Clinical Trials for Endeavor Drug Eluting Stent
Guidant’s Clinical Trials for Coronary Stent Demonstrates Positive Results

6.CLINICAL TRIALS UNDERTAKEN FROM 2002-2007

MIV Commences Clinical Trials of HC Stent
XTNT Voiced CUSTOM III Trial Program of NX™ DES System
Dynatek Completes DES Coating Durability Trial
STEALTH Trial
SIROCCO Trial
Cook Trial
ZoMAXX Trial
Ravel Trial
Sirius Trial
C - Sirius Trial
E - Sirius Trial
Taxus I through VI Clinical Trials
Other Clinical Trials

7.PRODUCT INNOVATIONS/INTRODUCTIONS

Abbott Receives European Clearance for Bioabsorbable Stent
NIMS Develops Am80 Drug Eluting Stent
Cook Medical Unveils New CE Marked Zilver PTX Drug-Eluting Peripheral Stent
Medtronic Rolls Out Driver Sprint RX Coronary Stent System
Boston Scientific Launches TAXUS Liberte DES In Japan

8.PRODUCT INNOVATIONS/INTRODUCTIONS – A HISTORIC PERSPECTIVE BUILDER

Medtronic Unveils Endeavor Sprint Drug-Eluting Stent in The US
CeloNova Unveils CATANIA™ Stent System with NanoThin Polyzene®-F
Abbott Launches Xience V Drug-Eluting Coronary Stent in Europe
Boston Introduces Taxus(R) Express2(TM) in Japan
Cordis Brings Advanced Drug-Eluting Stent
Sorin Unveils Enhanced Janus Flex in Europe
EUREKA Develops Latest Generation of Drug- Eluting Stent
MIV Therapeutics Develops New Drug Eluting Coating Technology in Canada
Medtronic to Launch Endeavor DES in Europe
DISA Vascular (Pty) Ltd Introduces ChromoFlex in Europe
Boston Scientific Introduces Taxus Liberte Drug Eluting Stent in Europe
Boston Scientific Introduces Innovative Drug-Eluting Stent, Taxus in the US Market

9.RECENT INDUSTRY ACTIVITY

Boston Scientific Obtains CE Mark Approval for TAXUS Element™
Biosensors Takes Over Cardiomind
Tryton Medical Implants First Tryton® in Austria and Portugal
Medtronic to Take Over Invatec
Abbott Obtains Approval for XIENCE V Stent System in Japan
Boston Scientific Obtains Approval for Promus Stent In Japan
Opto Circuits (India) Obtains CE Mark Approval for Taxcor Plus
Abbott Obtains Approval for Additional Indications of Xience V and Xience Prime
Bayer MaterialScience to Acquire PolyBioMed
Boston Scientific Obtains Health Canada Approval for PROMUS®
Abbott Labs to Introduce XIENCE V Stent in China
Abbott Obtains Approval for XIENCE V® from Health Canada
Boston Scientific Obtains FDA Approval for TAXUS® Liberte® Atom™ Stent
Medtronic Obtains CE Mark Approval for Endeavor DES
Biosensors International Group Receives CE Mark Approval for BioMatrix
Medtronic Receives Approval for Endeavor Drug-eluting Stent in Japan
Boston Scientific Obtains Japanese Approval for TAXUS® Liberte® Atom™
XTENT Receives CE Mark Approval for CUSTOM NX DES
Maxcor Lifescience Inks Strategic Cooperation Agreement with Micell Technologies
Boston Scientific Snaps Up Labcoat

10.INDUSTRY ACTIVITY – A HISTORIC PERSPECTIVE BUILDER

Medtronic Commences PROTECT Comparative Study in US
B.Braun to Invest in its India based Operations
Medtronic Secures TDP Approval for Endeavor Zotarolimus Eluting Coronary Stent
Medtronic Receives US FDA Approval for Endeavor Drug-Eluting Stent
Novation and Medtronic Ink National Agreement
MIV Therapeutics Acquires Biosync Scientific
J & J Acquires Conor Medsystems
FDA Approves Boston Scientifis’s Taxus Stent with Extended Shelf Life
Lombard Collaborates With S&N
India Establishes Asia’s first Catheter and Stent Unit.
Abbott Requests FDA Approval for Xience
Brookwood and TTV Start Joint Venture
SurModics Acquires Brookwood Pharmaceuticals, Inc
ARIAD Collaborates with ICON Medical
Biosensors Acquires 50% Stake in JWMS
Cordis’ Cypher Select™ Plus Receives Approval in Europe
Boston Scientific Acquires Guidant for $27 Billion, Abbott Gets Guidant’s Vascular and Cardiac Therapies Businesses as Part of Deal
Conor COSTAR II Receives US FDA Approval
Abbott Expands Vascular Sites in Ireland
Medtronic’s Endeavor® Attains Reimbursement Approval in France
SurModics Offers License for Hydrophilic Technology to Devax
Conor obtains License for Novartis’ Pimecrolimus
Medtronics Makes Final PMA Submission for Endeavor
Volcano Collaborates with CRF, Cardialysis and Stanford University
Boston’s PROMUS Receives CE Mark Approval
SurModics and X-Cell Inks Licensing Agreement
Medtronic Receives Regulatory Approval for Endeavor (R)
Medtronics’ Endeavor Obtains Chinese Regulatory Approval
Biosensors Collaborates with JW Medical
Biosensors and Weigao To Consolidate Joint Venture
Biotronik Enters Multi-Drug Deal with Novartis
MIVT Enters Collaboration Deal with SMT
SMT’s Infinnium Paclitaxel System Receives CE Mark
Guidant’s Xience V Receives European Approval
Medtronic Files Initial PMA Module TO US FDA
Boston Scientific Receives European Approval for TAXUS(R)
Biosensors Attains US Patent Covering DES Technology
MediVas LLC and Estracure Inc Sign Agreement for Development of DES
Relisys Medical of India Finalizes Deal with Germany Based Blue Membranes
X-cell Medical Enrolls for Clinical Trial of ETHOS I Estradiol Eluting Stent.
Biosensors International Group Receives CE Approval for First DES, Axxion
Boston Scientific Corp Receives CE Mark Approval for Marketing Larger Stent Sizes
Medtronic Receives CE Mark Approval for Commercial Sale of Endeavor DES in Europe
Biosensors International Opens New Interventional Cardiology Unit in Singapore
Johnson & Johnson Recalls Cypher Drug-Eluting Stents
Boston Scientific Buys Out Precision Vascular Systems
Implant Sciences and CardioTech International enter into Partnership with CorNova
Avantec Vascular Corporation Signs Agreement with Novartis Pharma AG
Guidant and Cordis Enter into Promotion Agreement
Genvec Collaborates with Cordis
Cordis Receives Approval from Japanese Ministry of Health
Boston Scientific Modifies Production of Taxus Drug-Eluting Stent
Guidant Acquired CE Mark Approval for Multi-Link Bifurcation Stent System
Boston Scientific Receives Reimbursement Approval from French Government
Boston Scientific Withdraws Consortium of Drug-Coated Stents

11.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Vascular (USA)
Boston Scientific, Inc. (USA)
Biosensors International Pte Ltd. (Singapore)
Medtronic, Inc.(USA)
MIV Therapeutics, Inc. (Canada)

12.GLOBAL MARKET PERSPECTIVE

Table 9. World Recent Past, Current and Future Analysis for Drug-Eluting Stents by Geographic Region – US, Japan, Europe and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 10. World Historic Review for Drug-Eluting Stents by Geographic Region – US, Japan, Europe and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 11. World 15-Year Perspective for Drug-Eluting Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of the World Markets for Years 2003, 2011, & 2017 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. Market Analysis
Issues and Trends
US Healthcare Ideology
The Important Role of Medicaid in the US
Boston Leads the DES Market

Table 12. US Drug Eluting Stents Market (2011): Market Share Breakdown by Leading Players – Boston Scientific, Abbott, Medtronic, and Johnson & Johnson (includes corresponding Graph/Chart)
Table 13. US Drug Eluting Stents Market (2011): Market Share Breakdown by Leading Brands – Xience V, Promus/Element, Taxus, Cypher, and Endeavor/Resolute(includes corresponding Graph/Chart)

Drug-Eluting Stents Launched in the US by Major Manufacturers (2003-2012)
Select Leading DES Products in the Market
Xience V – The Leader
Taxus and Promus– The Other Leading DES
Regulatory Environment
FDA Framework
FDA Approvals
B. Market Analytics

Table 14. The US Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 15. The US Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2.JAPAN

A. Market Analysis
Healthcare System in Japan

Table 16. Japanese Market for Drug Eluting Stents (2005-2007): Market Share Breakdown of Sales Revenue by Major Players- Johnson & Johnson Boston Scientific, and Medtronic

B. Market Analytics

Table 17. Japanese Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 18. Japanese Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

3.EUROPE

A. Market Analysis
Issues and Trends
Reimbursement Woes Continue in Europe
Reimbursement - A Major Hurdle in European Market Penetration of DES
Slow Market Penetration of New Medical Devices in Europe
Taxus – Leading the European Stent Market
Healthcare System in Europe
B. Market Analytics

Table 19. European Recent Past, Current and Future Analysis for Drug-Eluting Stents by Geographic Region – France, Germany, Italy, UK, Spain and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) (includes corresponding Graph/Chart)
Table 20. European Historic Review for Drug-Eluting Stents by Geographic Region – France, Germany, Italy, UK, Spain and Rest of the Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 21. European 15-Year Perspective for Drug- Eluting Stents by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

3A.FRANCE

A. Market Analysis
Healthcare System in France
B. Market Analytics

Table 22. French Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 23. French Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

3B.GERMANY

A. Market Analysis
Healthcare Policies in Germany
Lower Market Penetration of DES
B. Market Analytics

Table 24. German Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 25. German Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

3C.ITALY

A. Market Analysis
Italian Healthcare System
Local Healthcare Agencies
National Health System in Italy
B. Market Analytics

Table 26. Italian Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 27. Italian Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

3D.THE UNITED KINGDOM

A. Market Analysis
National Health System in the UK
B. Market Analytics

Table 28. The UK Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 29. The UK Historic Review for Drug- Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

3E.SPAIN

A. Market Analysis
Healthcare System in Spain
B. Market Analytics

Table 30. Spanish Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 31. Spanish Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

3F.REST OF EUROPE

Market Analytics

Table 32. Rest of European Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 33. Rest of European Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

4.REST OF WORLD

A. Market Analysis
Chinese Drug-Eluting Stents Market Witnesses Robust Growth
B. Market Analytics

Table 34. Rest of the World Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 35. Rest of World Historic Review for Drug- Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 39 (including Divisions/Subsidiaries - 46)
The United States (26)
Canada (3)
Japan (1)
Europe (11)
- Germany (2)
- The United Kingdom (3)
- Italy (1)
- Rest of Europe (5)
Asia-Pacific (Excluding Japan) (4)
Africa (1)
Skip to top


The Drug-Eluting Stent Market Outlook to 2016 US$ 3,835.00 Mar, 2011 · 115 pages

Ask Your Question

Drug-Eluting Stents: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: